Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT Capsule for Steroid-refractory GI-aGVHD
NCT04622475Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Nov 2020
- Primary completion
- Aug 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Open-label, single-arm trial of Fecal Microbiota Transplantation Capsule in graft-versus-host disease (GVHD), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: Number of adverse events (AEs)/serious adverse events (SAEs) at 28 days and Severity of AEs/SAEs at 28 days. Status: unknown.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04622475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622475.